The purpose of this study is to determine if therapy with angiotensin converting enzyme (ACE) inhibitor therapy is more beneficial than a placebo (no therapy) in preventing progression of renal insufficiency and eliminating proteinuria in patients with sickle cell nephropathy (a kidney disorder that is caused by Sickle Cell disease).
Showing the most recent 10 out of 782 publications